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Abstract
Introduction We aimed to establish whether the use of
nonsteroidal anti-inflammatory drugs (NSAIDs) during evolving
bacterial community-acquired infection in adults is associated
with severe sepsis or septic shock.
Methods We conducted a multicentre case-control study in
eight intensive care units. Cases were all adult patients admitted
for severe sepsis or septic shock due to a bacterial community-
acquired infection. Control individuals were patients
hospitalized with a mild community-acquired infection. Each
case was matched to one control for age, presence of diabetes
and site of infection.
Results The main outcome measures were the proportions of
cases and controls exposed to NSAIDs or aspirin during the
period of observation. In all, 152 matched pairs were analyzed.
The use of NSAIDs or aspirin during the observation period did
not differ between cases and controls (27% versus 28; odds
ratio = 0.93, 95% confidence interval [CI] = 0.52 to 1.64). If
aspirin was not considered or if a distinction was made between
acute and chronic drug treatment, there remained no difference
between groups. However, the median time to prescription of
effective antibiotic therapy was longer for NSAID users (6 days,
95% CI = 3 to 7 days) than for nonusers (3 days, 95% CI = 2
to 3 days; P = 0.02).
Conclusions In this study, the use of NSAIDs or aspirin during
evolving bacterial infection was frequent and occurred in one-
quarter of the patients with such infection. Although the use of
NSAIDs by patients with severe sepsis or septic shock did not
differ from their use by those with mild infection at the same
infected site, we observed a longer median time to prescription
of effective antibiotic therapy in NSAID users.
Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin are
widely used as antipyretic or analgesic drugs, even during
evolving bacterial infections. Previous authors have described
life-threatening infections associated with their use, mainly
streptococcal infections and necrotizing fasciitis [1-4]. The
involvement of NSAIDs in aggravation of bacterial infection is
a matter of controversy [5,6]. A number of case reports con-
CI: confidence interval; ICU: intensive care unit; NSAID: nonsteroidal anti-inflammatory drug; OR: odds ratio.Critical Care    Vol 13 No 2    Legras et al.
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cerning patients admitted to intensive care units (ICUs) have
suggested that the use of NSAIDs increases the severity of
bacterial infections and may lead to shock and multiple organ
failure [7-10]. In the present study we investigated whether
exposure to NSAIDs or aspirin affects the evolution of bacte-
rial infection.
Materials and methods
We carried out a multicentre case-control study in eight med-
ical or polyvalent ICUs.
Study population
All of the included patients were older than 15 years and had
a bacterial community-acquired infection. All of the cases were
patients admitted to an ICU with severe sepsis or septic shock
[11,12]. Patients with one or more of the following were
excluded: chronic kidney failure (creatinine clearance <30 ml/
min), pregnancy, nosocomial infection, or congenital or
acquired immunosuppression. Immunosuppression was
defined as the presence of metastatic neoplasia, haemopathy,
aplasia before the onset of sepsis, AIDS (independently of
CD4+ T-cell count) and chronic administration of immunosup-
pressive treatments, such as corticosteroids (equivalent of
>30 days of prednisone at dosage >0.5 mg/kg per day), anti-
neoplastic drugs or anti-tumour necrosis factor drugs.
Control individuals were patients admitted to hospital for mild
bacterial community-acquired infection, defined as infection
without any signs of severe sepsis or septic shock from the
onset of the disease to their discharge from the hospital. Each
case was matched to one control for age (± 10 years), pres-
ence of diabetes mellitus and site of infection (lung, urinary
tract, skin and soft tissue, abdomen, genital tract, joints, heart,
central nervous system or primary bloodstream). Diabetes was
chosen for the matching process because it is a frequent
chronic condition that increases the risk for severe infection.
The site of infection was chosen for the matching process
because the use of NSAIDs might differ depending on site of
infection. The type of micro-organism was not considered in
the matching process because bacterial documentation was
not always available during sepsis.
This study was observational and did not require any deviation
from routine practice. Our regional ethics review board
approved the study. Informed consent was not required.
Study design
For cases, the observation period began 2 days before the
onset of infection, defined as the appearance of the first signs,
and lasted until the beginning of severe sepsis or shock. Con-
trols were observed for the same period (Figure 1). The dura-
tion of observation varied from one case-control pair to
another, but it was identical for each case and matched con-
trol. NSAID use was quantified by careful listing of all of the
drugs taken during the observation period, and standard inter-
views were conducted by physicians. An exhaustive list of all
oral and parenteral NSAIDs (including their international non-
proprietary name and brand name) was provided to each
investigator. All NSAIDs and aspirin were considered. How-
ever, when aspirin was taken as an antiplatelet aggregant for
the prevention of cardiovascular diseases (<350 mg/day), it
was not taken into account. All types of oral and parenteral
NSAID administration were considered (acute or chronic, pre-
scribed or self-administered), whatever the duration or dos-
age. We defined acute administration of NSAIDs as their use
for the observation period only, and chronic administration as
their use for a chronic disease before that period.
Because most of the cases could not be interviewed on their
admission to the ICUs, the recording of their medical history
required the help of their relatives and general practitioner, as
well as reference to previous prescriptions. Antibiotic therapy
was studied and was considered effective if it exhibited appro-
priate in vitro activity and was appropriate for the pathogens
isolated (or, in the case of culture-negative bacterial infection,
Figure 1
Observation period Observation period. The observation period for both cases and controls began 2 days before the onset of infection, and for the cases it lasted until 
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for the suspected pathogens, based on international antibiotic
therapy guidelines).
The main outcome measures of the study were the respective
proportions of cases and controls who took prescribed or self-
administered NSAIDs or aspirin during the observation period.
We also compared, among the cases, the time from the first
signs of infection to effective antibiotic therapy among NSAID
users and nonusers.
Statistical analysis
The study was planned as an investigation of matched pairs
(one-to-one). Assuming an NSAID use rate of 20% among the
controls and an odds ratio (OR) of two, we planned to recruit
150 pairs (alpha and beta risks were respectively fixed at 5%
and 20%). ORs were estimated from discordant pairs, and
exact 95% confidence intervals (CIs) were computed from the
tail probabilities of the binomial distribution [13]. Adjustments
for parameters whose distribution among cases and controls
differed significantly were made within the framework of con-
ditional logistic regression. Finally, the time to effective antibi-
otic therapy among cases was assessed using the Kaplan-
Meier method, and NSAID users and nonusers were com-
pared using the log-rank test [14]. Data were analyzed using
SAS 9.1 software (SAS Institute Inc., Cary, NC, USA). Unless
otherwise stated, values are expressed as mean ± standard
deviation.
Results
We recruited 152 cases from February 2004 to November
2005. They were matched to 152 controls. Table 1 shows the
baseline characteristics of the cases and controls. Diabetes
was present in 20 pairs (13%). The sites of infection were the
lung (71 [47%]), urinary tract (30 [20%]), skin or soft tissues
(16 [11%]), heart (11 [7%]), abdomen (10 [7%]), central nerv-
ous system (8 [5%]), joints (4 [3%]) and primary bloodstream
(2 [1%]). A higher percentage of cases than controls had pre-
existing neoplastic disease, chronic hepatopathy, were smok-
ers or had a higher McCabe disease severity score. A higher
percentage of controls had rheumatic disease. The median
observation period for which total consumption of NSAIDs
was estimated was 6 days (interquartile range = 5 days to 10
days; the minimum and maximum were 3 days and 32 days,
respectively).
On inclusion, the characteristics of the 152 cases included
severe sepsis (34 [22%]) and septic shock (118 [78%]). The
mean Simplified Acute Physiology Score II was 49 ± 20. The
median length of stay in an ICU was 10 days (interquartile
range = 4 days to 17 days). During hospitalization in an ICU,
circulatory failure was present in 134 cases (88%), respiratory
failure in 101 (67%), kidney failure in 79 (52%) and haemato-
logical failure in 37 (24%).
Bacteriological identification revealed the presence of one or
more organisms in 123 out of 152 cases. The main organisms
Table 1
Baseline characteristics of the 152 pairs of matched cases and controls
Characteristics Cases (n = 152) Controls (n = 152) P
Male sex (n [%]) 90 (59) 87 (57) 0.73
Age (years; mean ± SD)a 60 ± 15 61 ± 16 0.67
Body mass index (kg/m2; mean ± SD) 26 ± 6 26 ± 5 0.91
Current smoking (n [%]) 57 (37) 38 (25) 0.02
Pre-existing disease (n [%]) 54 (35) 62 (41) 0.34
Chronic respiratory failure (n [%]) 22 (14) 15 (10) 0.22
Chronic heart failure (n [%]) 12 (8) 14 (9) 0.68
Moderate chronic kidney failure (CrCl >30 ml/minute; n [%]) 6 (4) 4 (3) 0.52
Chronic hepatopathy (n [%]) 12 (8) 4 (3) 0.04
Pre-existing neoplastic disease (n [%]) 12 (8) 2 (1) 0.01
Chronic rheumatic disease (n [%]) 13 (9) 30 (20) 0.01
McCabe disease severity score (n [%])
1 125 (82) 149 (98) < 0.001
2 27 (18) 3 (2)
3 00
aAlthough age was a matching factor, a statistical test was performed because the matching window was fixed at ± 10 years. CrCl, creatinine 
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were Streptococcus pneumoniae (34 [28%]), Escherichia coli
(29 [24%]), Staphylococcus aureus (19 [15%]) and Strepto-
coccus pyogenes (7 [6%]). Antibiotic therapy before admis-
sion to an ICU proved ineffective in 74 cases (33%).
Treatments included mechanical ventilation in 124 cases
(82%), vasopressive drugs in 128 (84%), dialysis in 35 (23%),
corticosteroids in 107 (70%) and drotrecogin alpha in 33
(22%). Surgery was performed to treat the origin of sepsis in
40 (26%) of the cases. The mortality rate in the ICUs among
the cases was 24%.
All controls had a mild bacterial community-acquired infection.
The median length of their hospital stay was 7 days (interquar-
tile range = 5 days to 14 days). None of them developed
severe sepsis or septic shock, none were admitted to an ICU
and none died. Bacteriological identification revealed the pres-
ence of one or more micro-organisms in 75 out of 152 controls
(49%). The main organisms were Escherichia coli (29 [39%]),
Staphylococcus aureus (11 [15%]) and Streptococcus pneu-
moniae (7 [9%]). Only one Streptococcus pyogenes infection
was identified.
The use of NSAIDs or aspirin during the observation period
did not differ between cases and controls (27% versus 28;
OR = 0.93, 95% CI = 0.52 to 1.64; P = 0.79; Table 2). If aspi-
rin was not considered, there was still no difference, and no
difference either when acute and chronic NSAID treatments
were considered separately. If aspirin was not considered or if
acute and chronic NSAID treatment were considered sepa-
rately, there remained no difference between groups. Whether
Table 2
Comparison of NSAID and aspirin use by cases versus controls
Analysis NSAID users (%) OR (95% CI) P value
Cases Controls
Global (n = 152)a NSAIDs and aspirin 27 28 0.93 (0.52 to 1.64) 0.79
NSAIDs 24 21 1.18 (0.64 to 2.19) 0.56
Chronic treatment 4 5 0.86 (0.24 to 2.98) 0.78
Acute treatment 20 16 1.40 (0.69 to 2.92) 0.32
Aspirin 5 10 0.47 (0.16 to 1.22) 0.09
Subgroup analysis Diabetes (n = 20)a
NSAIDs 20 5 4.00 (0.40 to 196.99) 0.18
Aspirin 10 5 2.00 (0.40 to 196.99) 0.56
No diabetes (n = 132)a
NSAIDs 24 23 1.05 (0.55 to 2.00) 0.88
Aspirin 4 11 0.36 (0.10 to 1.05) 0.04b
Site of infection: lung (n = 71)a
NSAIDs 14 15 0.90 (0.32 to 2.46) 0.82
Aspirin 7 11 0.63 (0.16 to 2.17) 0.40
Site of infection: urinary tract (n = 30)a
NSAIDs 27 30 0.83 (0.02 to 3.28) 0.76
Aspirin 3 7 0.50 (0.01 to 9.60) 0.56
Site of infection: skin and soft tissue (n = 16)a
NSAIDs 31 31 1.00 (0.07 to 13.80) 1.00
Aspirin 0 6 - - -
Site of infection: other (n = 35)a
NSAIDs 37 20 2.50 (0.72 to 10.92) 0.11
Aspirin 3 11 0.25 (0.01 to 2.53) 0.18
aThe n values indicate the number of pairs. bThe apparent discordance between the confidence interval (CI) and statistical test results is due to 
the use of different but asymptotically equivalent statistical methods. NSAID, nonsteroidal anti-inflammatory drug; OR, odds ratio.Available online http://ccforum.com/content/13/2/R43
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the duration of exposure taken into account was 1 day, more
than 1 day or more than 2 days, or whether the end of the
observation period was defined as the day of hospital admis-
sion rather than the beginning of severe sepsis or shock,
NSAID or aspirin ingestion did not differ between cases and
controls (data not shown).
Finally, there was still no difference between the two groups
after adjustment for pre-existing diseases or for treatment cen-
tre (data not shown). Few diabetic patients were included in
the study (only 20 pairs). There was no difference between
their NSAID or aspirin consumption and that of the rest of the
population studied. However, more nondiabetic controls than
cases used aspirin (11% versus 4%; OR = 0.36; P = 0.04).
For the three main sites of infection (lung, urinary tract, and
skin or soft tissue), NSAID use varied depending on the site.
Twice as many cases and controls with urinary tract or skin
and soft tissue infections used NSAIDs compared with those
who had lung infections. We did not observe any difference
between cases and controls for any of the sites studied.
Consequently, in the light of these findings, only the cases
were studied. Among the cases, the time from the first signs to
the prescription of effective antibiotic therapy was longer for
NSAID users than for nonusers (median [95% CI]: 6 days, 3
days to 7 days for NSAID users versus 3 days, 2 days to 3
days for NSAID nonusers; P = 0.02; Figure 2). Among the
cases, the mortality rate in NSAID users was 27% and that in
nonusers was 23% (P = 0.58).
Discussion
The findings presented here do not support the hypothesis
that NSAID exposure during evolving bacterial infection is
associated with an increased risk for severe sepsis or septic
shock. However, in patients with severe sepsis or septic shock
we observed that NSAID use is associated with a longer time
from the first signs of infection to prescription of effective anti-
biotic therapy.
As stated in the Introduction (above), several case reports for
patients admitted to ICUs [7-9] have suggested that NSAID
treatment might increase the severity of infection and lead to
shock and multiple organ failure. This is because life-threaten-
ing infections – mainly streptococcal, especially necrotizing
fasciitis – have been described following NSAID use [3,5], as
have infections with other organisms such as Staphylococcus
spp. or Gram-negative bacilli, albeit less frequently [15]. How-
ever, unlike these case reports, case-control studies are
designed to establish an association between an event and a
risk factor and to quantify the risk involved. Most of the case-
control studies relevant to the present investigation concerned
the link between NSAID exposure of children with varicella and
skin or soft tissue infections [16-19]. A significant association,
which persisted after adjustment for age, sex and infection by
micro-organisms (streptococci and other organisms), was
found between ibuprofen use and necrotizing fasciitis [19].
This finding is particularly interesting, because the protopathic
bias of the study was limited, as all cases had necrotizing fas-
ciitis and all controls had severe post-varicella skin or soft tis-
sue infections. As far as we know, our study is the first case-
control investigation to focus on adults with community-
acquired bacterial infections. Because the incidence of skin
and soft tissue infections in ICUs is lower than that of lung or
urinary tract infections [20], we included patients with many
kinds of severe bacterial infections generally admitted to ICUs.
The main site of infection was lung, for which fewer patients
were given NSAIDs than for other infected sites, followed by
urinary tract.
Several possible explanations can be suggested for our inabil-
ity to find a link between NSAID use and increased risk for sep-
sis during bacterial infection. First, the sites of infection and
micro-organisms that we identified, especially the low inci-
dence of skin and soft tissue infections and consequently of
streptococcal infections, differ from those most frequently
identified in studies that found a link between NSAID and sep-
sis. We included various kinds of bacterial community-
acquired infections, and among the 16 case/control pairs with
skin and soft tissue infections Streptococcus pyogenes was
identified in just seven cases and one control. Second, more
microbiological documentation was available for cases than
controls. However, this was not surprising, because the inci-
dence of bacteraemia is usually higher in severe sepsis and
septic shock, and because lung samples are more frequently
available in patients with mechanical ventilation than in those
without. The resulting high rate of undocumented infection in
the control group may have biased the results of the study.
Figure 2
Time from the first signs of infection to effective antibiotic therapy Time from the first signs of infection to effective antibiotic therapy. 
Shown is a comparison of the times from the first signs of infection to 
effective antibiotic therapy for cases; the compared groups were cases 
using nonsteroidal anti-inflammatory drugs (NSAIDs) and those not 
using these drugs. Log-rank test: P = 0.02.Critical Care    Vol 13 No 2    Legras et al.
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Finally, it is possible that we underestimated NSAID use
among the cases. However, we assumed that more cases than
controls took NSAIDs because the cases were more severely
ill, and that NSAIDs were prescribed or self-administered to
manage pain or fever. Such underestimation of NSAID use
could have been due to the greater difficulty of assessing drug
use in severely ill patients than in controls with mild infection,
whose interviews provided more accurate information. Family
questioning and analysis of initial prescriptions were mostly
used in cases, and direct questioning in controls.
Other possible explanations for our negative findings are as
follows: the study might have been underpowered (for
instance, as a result of overestimation of NSAID use in cases);
there may have been a sampling bias if the true population
using NSAIDs was not representative of either the cases or
the controls; and the patients with the most severe septic
shock might have had no time to use NSAIDs.
Although the patients included in our study were suffering
from ongoing infection, many had started taking NSAIDs
before the beginning of effective antibiotic therapy. Among the
cases, the median time from the first signs of infection to pre-
scription of effective antibiotic therapy was twice as long for
NSAID users as for nonusers (Figure 2). This was in agree-
ment with the observations reported by Zerr and coworkers
[19], who found a longer duration of secondary symptoms
before hospitalization in NSAID-exposed than in NSAID-unex-
posed patients [19]. These findings suggest that NSAIDs
probably delay the prescription of effective antibiotic therapy
because they may mask the progression of disease by sup-
pressing the inflammatory response induced by the infection
[21,22]. This is a very important consideration, because delay
in diagnosis and consequently in the administration of effective
antibiotic therapy was recently shown to be one of the main
risk factors for mortality [23].
The potentially harmful effect of NSAIDs may vary, depending
on whether patients receive effective antibiotic therapy.
Although this was not taken into account in our study, we
observed higher mortality, albeit not significantly so, in NSAID-
exposed patients. Certain other authors aimed to demon-
strate, in contrast, that NSAIDs have a beneficial effect during
sepsis, as observed in animals, and that inhibition of cyclo-oxy-
genase activity improves survival and reduces the physiologi-
cal abnormalities caused by sepsis [22]. In adults given
effective antibiotic therapy for sepsis, some investigators
found no difference in clinical outcomes between NSAID
users and nonusers, despite a decrease in prostacyclin metab-
olites in users [24-26]. However, the latter findings do not rule
out the possibility that NSAIDs might be harmful in patients
given ineffective antibiotic therapy. In any case, these drugs
may predispose to severe bacterial infections because they
inhibit leucocyte adherence, phagocytosis and bactericidal
activity in vitro [22]. In addition, because NSAIDs have been
found to increase inflammatory cytokine production in animal
and human studies [24,27,28], and because the mortality rate
for sepsis correlates with high interleukin-6 and tumour necro-
sis factor-α levels, the use of prostaglandin inhibitors in sepsis
may be harmful. From this point of view, it might be useful to
study infections that are more directly linked to the impairment
of granulocyte function, such as fasciitis, extensive abscesses
or collections of bacteria from different sites, rather than
severe sepsis or septic shock, which are mainly the conse-
quence of the systemic inflammatory reaction.
Conclusions
The prescribed or self-administered use of NSAIDs is frequent
during evolving bacterial infection, but in the present study it
did not differ between patients with mild community acquired-
infection and those with severe sepsis or septic shock. Our
results therefore do not support the hypothesis that, during
bacterial community-acquired infection, NSAIDs increase the
risk for severe sepsis or septic shock. Nevertheless, NSAID
use was associated with delayed prescription of effective anti-
biotic therapy. Further studies are needed to establish the
effects of NSAIDs on patients whose antibiotic therapy is not
effective, and whether NSAID use increases the morbidity of
bacterial infections such as fasciitis or extensive abscesses,
rather than the frequency of severe sepsis and septic shock.
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